Quince Therapeutics, Inc. (QNCX)
$
1.6
+0.06 (3.75%)
Key metrics
Financial statements
Free cash flow per share
-0.6412
Market cap
85.9 Million
Price to sales ratio
511.5600
Debt to equity
1.4806
Current ratio
5.0013
Income quality
0.6916
Average inventory
0
ROE
-1.8608
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to advancing precision therapeutics aimed at addressing debilitating and rare diseases. The company has developed a unique bone-targeting drug platform that facilitates the precise delivery of small molecules, peptides, or large molecules directly to the sites of bone fractures and diseases. Its lead compound, NOV004, is an anabolic peptide specifically engineered to target and concentrate at these bone fracture sites. The company, which was originally incorporated as Cortexyme, Inc. in 2012, underwent a name change to Quince Therapeutics, Inc. in August 2022. As a measure of operational profitability, the EBITDA is -$56,555,000.00 reflecting the company's financial health. The diluted EPS is -$1.31 which accounts for potential share dilution, providing insight into expected earnings per share after considering all convertible securities. Additionally, the weighted average number of shares outstanding is 43,262,269.00 highlighting the company's shareholder base. The company's stock is actively traded and is identified with the symbol 'QNCX' in the market. Furthermore, the company incurred an income tax expense of $87,000.00 indicating its financial obligations regarding taxes. The stock of Quince Therapeutics, Inc. is affordable at $1.78 appealing to budget-conscious investors looking for cost-effective opportunities. It has an average trading volume of 246,034.00 which indicates moderate liquidity, thus providing investors with a decent opportunity for entry and exit. The company is classified as a small-cap player with a market capitalization of $85,942,080.00 reflecting its size within the industry. As a key player in the Biotechnology industry, Quince Therapeutics contributes significantly to the overall market landscape, indicating its role in fostering advancements within the field. Additionally, it belongs to the Healthcare sector, driving innovation and growth, thus playing a vital role in the evolution of therapeutic solutions.
Is Quince Therapeutics, Inc. (QNCX) a good investment?
Investing in Quince Therapeutics, Inc. (QNCX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Quince Therapeutics, Inc. (QNCX)'s stock forecast?
Analysts predict Quince Therapeutics, Inc. stock to fluctuate between $0.66 (low) and $2.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Quince Therapeutics, Inc.'s market capitalization?
As of 2025-08-29, Quince Therapeutics, Inc.'s market cap is $85,942,080, based on 53,713,800 outstanding shares.
How does Quince Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Quince Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Quince Therapeutics, Inc. (QNCX) stock?
To buy Quince Therapeutics, Inc. (QNCX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QNCX. Place an order (Market, Limit, etc.).
What is the best time to invest in Quince Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Quince Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.31 | Growth: 55.95%.
Where can I find Quince Therapeutics, Inc.'s investor relations reports?
Visit https://www.quincetx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Quince Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Quince Therapeutics, Inc. stock?
All-time high: $2.72 (2022-08-11) | All-time low: $0.51 (2024-08-15).
What are the key trends affecting Quince Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
19 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “We achieved many critical milestones over the last quarter.
businesswire.com
a month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Tel.
businesswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). D.
businesswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., ke.
businesswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the closing of its previously announced sale and issuance to certain institutional and accredited investors, of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”) that resulted in ap.
businesswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”).
businesswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a to.
seekingalpha.com
4 months ago
Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the open-label extension, and cash runway aligns with expected topline results.
businesswire.com
4 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “In light of current cash runway and with the goal of maxim.
businesswire.com
4 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation.
See all news
